Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.72 |
| ▸ | PPARA | Q07869 | 15/20 | 0.72 |
| ▸ | PPARD | Q03181 | 4/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5393093 | 1.00 | PPARG (0.72) | PPARGPPARAPPARDITGB3ITGA2B | |
| SCHEMBL5386839 | 0.95 | PPARA (0.71) | PPARGPPARAPPARDITGB3ITGA2B | |
| SCHEMBL5991816 | 0.91 | PPARA (0.60) | PPARGPPARAPPARDITGB3ITGA2B | |
| SCHEMBL6818773 | 0.91 | PPARA (0.60) | PPARGPPARAPPARDITGB3ITGA2B | |
| SCHEMBL5388906 | 0.91 | PPARA (0.60) | PPARGPPARAPPARDITGB3ITGA2B | |
| SCHEMBL5991504 | 0.90 | PPARA (0.59) | PPARGPPARAPPARDITGB3ITGA2B | |
| SCHEMBL5991875 | 0.89 | PPARA (0.66) | PPARGPPARAPPARD | |
| SCHEMBL5992983 | 0.89 | PPARA (0.61) | PPARGPPARAPPARD | |
| SCHEMBL5991768 | 0.89 | PPARA (0.58) | PPARGPPARAPPARDITGB3ITGA2B | |
| SCHEMBL5991079 | 0.88 | PPARA (0.57) | PPARGPPARAPPARDITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| EP-1528917-B1 | DOSAGE FORM COMPRISING HIGH DOSE HIGH SOLUBLE ACTIVE INGREDIENT AS MODIFIED RELEASE AND LOW DOSE ACTIVE INGREDIENT AS IMMEDIATE RELEASE | TORRENT PHARMACEUTICALS LTD (IN) | 2013-06-19 | — | — | EP | claimed |
| EP-1150678-B1 | USE OF 3-HYDROXY-3-METHYLGLUTARYL COENZYM A REDUCTASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETIC NEUROPATHY | ASTRAZENECA AB (SE) | 2007-07-18 | — | — | EP | claimed |
| EP-1404309-B1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL| PROPANOIC ACID OR 3- 4- 2- (4-TERT-BUTOXY CARBONYL AMINOPHENYL) ETHOXY| PHENYL -(S)-2-ETHOXY PROPANOIC ACID AND A BIGUANIDE DRUG | ASTRAZENECA AB (SE) | 2006-08-23 | — | — | EP | claimed |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL | 2006-08-03 | — | — | US | claimed |
| US-20060153916-A1 | Novel dosage form | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-07-13 | — | — | US | claimed |
| EP-1666034-A1 | Pharmaceutical combination comprising a biguanide | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | claimed |
| US-20050209128-A1 | Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy | ASTRAZENECA AB | 2005-09-22 | — | — | US | claimed |
| WO-2005065639-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2005-07-21 | — | — | WO | claimed |
| WO-2002100413-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- [4-(2-{4-METHANE SULFONYL OXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID OR 3-{4-[2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL} -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | claimed |
| WO-2002096453-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3 [4-(2- {4-METHANE SULFONYL OXYPHENYL} ETHOXY)PHENYL] PROPANOIC ACID OR 3-{4-[2- (4-TERT-BUTOXY CARBONYLAMINO PHENYL) ETHOXY] PHENYL}-(S)-2-ETHOXY PROPANOIC ACID AND INSULIN | ASTRAZENECA AB (SE) | 2002-12-05 | — | — | WO | claimed |
| WO-2002096402-A1 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- [4-(2- {4-METHANE SULFONYL OXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID OR 3-{4-[2- (4-TERT-BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL} -(S)-2-ETHOXY PROPANOIC ACID AND A BIGUANIDE DRUG | ASTRAZENECA AB (SE) | 2002-12-05 | — | — | WO | claimed |
| JP-2002536332-A | — | — | 2002-10-29 | — | — | JP | claimed |
| EP-1150678-A1 | USE OF 3-HYDROXY-3-METHYLGLUTARYL COENZYM A REDUCTASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETIC NEUROPATHY | AstraZeneca AB (SE) | 2001-11-07 | — | — | EP | claimed |
| WO-2001040166-A1 | COMMINUTED FORM OF 3-{4-[2-(4-TERT-BUTOXYCARBONYLAMINOPHENYL)ETHOXY]PHENYL}-(S)-2-ETHOXY PROPANOIC | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | claimed |
| WO-2001040165-A1 | CRYSTALLINE FORM OF 3-{4-[2-(4-TERT-BUTOXYCARBONYLAMINOPHENYL)ETHOXY]PHENYL}-(S)-2-ETHOXY PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | claimed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | claimed |
| WO-2000045818-A1 | USE OF 3-HYDROXY-3-METHYLGLUTARYL COENZYM A REDUCTASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETIC NEUROPATHY | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | claimed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | PPARG 22/4885PPARA 11/4885PPARD 8/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | PPARG 567/4885PPARA 787/4885PPARD 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.